A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO)
-
Enrollment
This study is not currently enrolling. -
Associated Conditions
-
Research Area
Clinical Cancer Research -
Sponsor
NRG Oncology